Related Experiment Video
Updated: May 20, 2026

Evaluation of a Reliable Biomarker in a Cecal Ligation and Puncture-Induced Mouse Model of Sepsis
Published on: December 9, 2022
STAT1-deficient mice are resistant to cecal ligation and puncture-induced septic shock
Daniela Herzig1, Geping Fang, Tracy E Toliver-Kinsky
1Department of Anesthesiology, The University of Texas Medical Branch and Shriners Hospital for Children, Galveston, Texas, USA.
Abstract:
STAT1 (signal transducer and activator of transcription 1) is a member of the JAK-STAT signaling family and plays a key role in facilitating gene transcription in response to activation of the types I and II interferon (IFN) receptors. TYK2 is essential for type I, but not type II, IFN-induced STAT1 activation. Previous studies show that STAT1-deficient mice are resistant to endotoxin-induced shock. The goal of the present study was to assess the response of STAT1- and TYK2-deficient mice to septic shock caused by cecal ligation and puncture (CLP). End points included survival, core temperature, organ injury, systemic cytokine production, and bacterial clearance. Results showed that survival rates were significantly higher in STAT1 knockout (STAT1KO) mice compared with wild-type controls (80% vs. 10%). The improved survival of STAT1KO mice was associated with less hypothermia, metabolic acidosis, hypoglycemia, and hepatocellular injury. Plasma interleukin 6, MIP-2, CXCL10, and IFN-α concentrations were significantly lower in STAT1KO mice than in wild-type mice. In the absence of antibiotic treatment, blood and lung bacterial counts were significantly lower in STAT1KO mice than in controls. However, treatment with antibiotics ablated that difference. A survival advantage was not observed in TYK2-deficient mice compared with control. However, CLP-induced hypothermia and systemic interleukin 6 and CXCL10 production were significantly attenuated in TYK2-deficient mice. These results indicate that STAT1 activation is an important factor in the pathogenesis of CLP-induced septic shock and is associated with the development of systemic inflammation and organ injury. TYK2 activation also appears to contribute to CLP-induced inflammation, but to a lesser extent than STAT1.
Insights
Mice lacking STAT1 (signal transducer and activator of transcription 1) showed improved survival and reduced organ injury during septic shock. TYK2 deficiency also attenuated inflammation but did not improve survival, indicating STAT1
Area of Science:
- Immunology and Molecular Biology
- Sepsis Pathogenesis
Background:
- Signal transducer and activator of transcription 1 (STAT1) is crucial for interferon receptor signaling and gene transcription.
- STAT1-deficient mice exhibit resistance to endotoxin-induced shock.
- Tyrosine kinase 2 (TYK2) is essential for type I interferon-induced STAT1 activation.
Purpose of the Study:
- To investigate the roles of STAT1 and TYK2 in the response to cecal ligation and puncture (CLP)-induced septic shock.
- To evaluate survival rates, organ injury, cytokine production, and bacterial clearance in STAT1- and TYK2-deficient mice.
Main Methods:
- Utilized STAT1 knockout (STAT1KO) and TYK2-deficient mouse models.
- Induced septic shock using the cecal ligation and puncture (CLP) model.
- Monitored survival, core body temperature, metabolic parameters, organ injury markers, plasma cytokine levels, and bacterial counts.
Main Results:
- STAT1KO mice demonstrated significantly higher survival rates (80% vs. 10%) compared to wild-type controls following CLP.
- Improved survival in STAT1KO mice was linked to reduced hypothermia, metabolic acidosis, hypoglycemia, and hepatocellular injury.
- STAT1KO mice exhibited lower plasma levels of IL-6, MIP-2, CXCL10, and IFN-α, and reduced bacterial load.
Conclusions:
- STAT1 activation is a critical factor in the pathogenesis of CLP-induced septic shock, contributing to systemic inflammation and organ damage.
- TYK2 plays a role in CLP-induced inflammation, but its absence does not confer a survival advantage.
- Targeting STAT1 may offer a therapeutic strategy for mitigating sepsis severity.

